JP2007504144A - セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 - Google Patents

セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 Download PDF

Info

Publication number
JP2007504144A
JP2007504144A JP2006524842A JP2006524842A JP2007504144A JP 2007504144 A JP2007504144 A JP 2007504144A JP 2006524842 A JP2006524842 A JP 2006524842A JP 2006524842 A JP2006524842 A JP 2006524842A JP 2007504144 A JP2007504144 A JP 2007504144A
Authority
JP
Japan
Prior art keywords
antitrypsin
serine protease
mammalian
anthrax
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006524842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504144A5 (cg-RX-API-DMAC7.html
Inventor
レランド シャピロ
Original Assignee
ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト filed Critical ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト
Publication of JP2007504144A publication Critical patent/JP2007504144A/ja
Publication of JP2007504144A5 publication Critical patent/JP2007504144A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006524842A 2003-08-26 2004-08-26 セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 Pending JP2007504144A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49770303P 2003-08-26 2003-08-26
PCT/US2004/027711 WO2005019434A2 (en) 2003-08-26 2004-08-26 Serine protease inhibitors for treatment of bacterial infections

Publications (2)

Publication Number Publication Date
JP2007504144A true JP2007504144A (ja) 2007-03-01
JP2007504144A5 JP2007504144A5 (cg-RX-API-DMAC7.html) 2007-12-27

Family

ID=34216145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524842A Pending JP2007504144A (ja) 2003-08-26 2004-08-26 セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法

Country Status (8)

Country Link
US (8) US7850970B2 (cg-RX-API-DMAC7.html)
EP (3) EP2520654B8 (cg-RX-API-DMAC7.html)
JP (1) JP2007504144A (cg-RX-API-DMAC7.html)
CA (1) CA2536918A1 (cg-RX-API-DMAC7.html)
DK (1) DK2520654T3 (cg-RX-API-DMAC7.html)
ES (1) ES2622522T3 (cg-RX-API-DMAC7.html)
PL (1) PL2520654T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005019434A2 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519852A (ja) * 2011-06-24 2014-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2014523900A (ja) * 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法
JP5729297B2 (ja) * 2009-07-13 2015-06-03 不二製油株式会社 経口性抗炎症剤及び経口性抗炎症ペプチド
JP2015519341A (ja) * 2012-05-25 2015-07-09 ウェル リソーシーズ リミテッド ペプチドおよびその使用
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1704867A1 (en) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008072A2 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
WO2007079312A2 (en) * 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
CN101443353A (zh) * 2006-03-15 2009-05-27 Csir公司 谷氨酰胺合成酶活性的调节
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
US8629139B2 (en) * 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
CA2806559C (en) 2009-09-02 2018-06-26 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
CN102724983A (zh) 2009-09-04 2012-10-10 Mpex医药有限公司 雾化左氧氟沙星治疗囊性纤维化的用途
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
IL214246B (en) * 2011-07-21 2018-08-30 Shafferman Avigdor Vaccines produced from htra-defective Bacillus anthraxis
US10220002B2 (en) 2011-12-02 2019-03-05 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
US9951104B2 (en) * 2012-01-09 2018-04-24 Serpin Pharma, Llc Peptides and methods of using same
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
CN103804484B (zh) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 一种网红细胞生长因子及其制备方法和应用
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
JP2017526714A (ja) 2014-09-11 2017-09-14 シネジェン， インコーポレイテッド 組成物およびその使用方法
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016196401A1 (en) * 2015-05-29 2016-12-08 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
JP6929272B2 (ja) 2015-08-28 2021-09-01 セルピン ファーマ リミテッド ライアビリティ カンパニー 疾患処置のための方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018183705A1 (en) 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
US11717519B2 (en) 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
WO2019178472A1 (en) * 2018-03-16 2019-09-19 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
AU2020444897A1 (en) * 2020-04-30 2022-12-08 Synedgen, Inc. Compositions and methods of use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
GB202214206D0 (en) * 2022-09-28 2022-11-09 Chariot Innovations Ltd Treatment
WO2024261179A1 (en) * 2023-06-22 2024-12-26 Aatec Medical Gmbh Recombinant aat from yeast to treat bacterial respiratory infections

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US500242A (en) * 1893-06-27 Superheating steam-coil
DE930013C (de) 1952-02-13 1955-07-07 E Gerspacher Fa Fuellhalter
GB800250A (en) 1956-03-27 1958-08-20 Chimie Atomistique New isonicotinic thioamides and their process of preparation
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US4668504A (en) 1970-11-18 1987-05-26 Merck & Co., Inc. Use of substituted propenoates to prevent nephrotoxicity of certain antibiotics
US3781268A (en) 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
GB1472700A (en) * 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5470241A (en) 1977-11-09 1979-06-05 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
GB2044760B (en) 1979-03-01 1983-03-23 Ono Pharmaceutical Co Guanidinobenzoic acid derivatives
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
JPS5634662A (en) 1979-08-31 1981-04-06 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
WO1986000337A1 (fr) 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US4760130A (en) 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
ES2039356T3 (es) 1985-11-12 1993-10-01 Ono Pharmaceutical Co., Ltd. Un procedimiento para la preparacion de derivados del acido p-guanidinobenzoico.
US5247084A (en) 1985-11-12 1993-09-21 Ono Pharmaceutical Co., Ltd. Derivatives of p-guanidinobenzoic acid
US4843094A (en) 1985-11-12 1989-06-27 Ono Pharmaceutical Co., Ltd. Derivatives of p-guantidinobenzoic acid and pharmaceutical agents containing them as active ingredient
US4629567A (en) 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US5157019A (en) * 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5093316A (en) * 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US4829054A (en) * 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
KR880012221A (ko) 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4963583A (en) 1987-10-05 1990-10-16 Ciba-Geigy Corporation Beta-ionone derivatives as antifungal agents
US4857538A (en) * 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US4963654A (en) * 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5019573A (en) 1989-09-19 1991-05-28 Euroceltique, S.A. Substituted dibenzofurans and methods of using same
JP2568281B2 (ja) 1989-11-17 1996-12-25 原田工業株式会社 自動車用三波共用アンテナ
US5714140A (en) 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
DE4009117A1 (de) 1990-03-19 1991-09-26 Schering Ag Neue leukotrien-b(pfeil abwaerts)4(pfeil abwaerts)-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU7999691A (en) 1990-06-07 1991-12-31 Smithkline Beecham Corporation Phthalamic acids and their isomers for treating leukotriene-related diseases
WO1991018880A1 (en) 1990-06-07 1991-12-12 Smithkline Beecham Corporation Benzoic acid derivatives for treating leukotriene-related diseases
AU655428B2 (en) 1990-06-07 1994-12-22 Smithkline Beecham Corporation Benzoic acid derivatives
HUT64521A (en) 1990-06-07 1994-01-28 Smithkline Beecham Corp Process for producing amidic bound pyridyl-benzoic acid derivatives and pharmaceutical preparatives containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
ATE146970T1 (de) 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
JP2548587Y2 (ja) * 1990-11-30 1997-09-24 シチズン時計株式会社 プリンタの印字ヘッド
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
WO1992018141A1 (en) 1991-04-18 1992-10-29 The Uab Research Foundation Compositions and methods for inhibiting elastase
US5175253A (en) * 1991-04-24 1992-12-29 Washington University Binding peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5216022A (en) * 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
EP0670737A4 (en) 1992-03-26 1996-05-29 Gensia Inc IN VIVO PEPTIDE THERAPY.
GB9209032D0 (en) 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
JP2736952B2 (ja) 1992-09-18 1998-04-08 小野薬品工業株式会社 アミジノフェノール誘導体およびその誘導体を有効成分として含有する薬剤
DE4242390A1 (de) 1992-12-09 1994-06-16 Schering Ag Neue Leukotiren-B¶4¶-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
DK0656349T3 (da) 1993-12-03 1998-06-02 Ono Pharmaceutical Co Amidinophenolderivater med inhiberende virkning på phospholipase A2
JPH0827371A (ja) 1994-05-09 1996-01-30 Japan Carlit Co Ltd:The 紫外線及び赤外線吸収樹脂組成物
US6090786A (en) 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5712117A (en) * 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
WO1997003679A1 (en) 1995-07-17 1997-02-06 Cephalon, Inc. Phosphorous-containing cysteine and serine protease inhibitors
WO1997010231A1 (en) 1995-09-14 1997-03-20 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
KR100356956B1 (ko) 1996-03-11 2003-03-15 베이어 코오포레이숀 사람비쿠닌
WO1997037969A1 (en) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
EP0915086A4 (en) 1996-05-24 2001-01-17 Ono Pharmaceutical Co PHENYLSULFONAMIDE DERIVATIVES
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AU3232597A (en) 1996-06-18 1998-01-07 Warner-Lambert Company Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors
KR20000022532A (ko) 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
US5616693A (en) * 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6372887B1 (en) 1996-11-07 2002-04-16 Heska Corporation Flea serine protease inhibitor proteins
AU7179598A (en) 1996-11-13 1998-06-03 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
RU2217436C2 (ru) 1996-12-06 2003-11-27 Кортеч, Инк. Производные оксадиазола, тиадиазола или триазола, являющиеся ингибиторами сериновых протеаз, и содержащие их фармацевтические композиции
US6150332A (en) 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
DE69823178T2 (de) 1997-05-02 2005-06-23 Akzo Nobel N.V. Serine protease inhibitoren
JP2002512621A (ja) 1997-05-08 2002-04-23 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
EP1150699A4 (en) 1999-02-01 2004-06-30 John Lezdey TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS
GB9904421D0 (en) 1999-02-25 1999-04-21 Univ Edinburgh Telecommunications receiver
JP2002537810A (ja) 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
WO2000052034A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3864000A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6489308B1 (en) * 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
AU3923000A (en) 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
EP1200124B1 (en) * 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
AU1101501A (en) * 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors
JP2003515325A (ja) 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
CN1328000A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——糖基磷脂酰肌醇聚糖f11.22和编码这种多肽的多核苷酸
US6955845B1 (en) 2000-06-30 2005-10-18 Owens Corning Fiberglas Technology, Inc. Acoustical and thermal insulator
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
KR20030070092A (ko) 2001-01-04 2003-08-27 바스큘라 바이오제닉스 리미티드 죽상경화증을 예방 및 치료하기 위한 플라크 관련 분자를함유하는 조성물 및 이 분자를 이용하는 방법
CN1547586A (zh) 2001-02-23 2004-11-17 ���鹫˾ 提高的活性蛋白回收率
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
IL159015A0 (en) 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease
US7393539B2 (en) * 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6924267B2 (en) * 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
WO2003059935A2 (en) * 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
AU2003245325A1 (en) * 2002-05-23 2003-12-12 Chiron Corporation Substituted quinazolinone compounds
AU2003252178A1 (en) * 2002-07-25 2004-02-16 Advances Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
DK1694342T3 (da) 2003-11-12 2021-02-08 Univ Pennsylvania Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
EP1682584B1 (en) 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
KR101300929B1 (ko) 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
WO2009005877A2 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
WO2007079312A2 (en) 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
ES2651268T3 (es) * 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
US20080199467A1 (en) 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2978442B1 (en) 2013-03-29 2020-03-18 The Regents of the University of Colorado, a body corporate Alpha 1 antitrypsin of use for preparing a subject for transplant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010042299, ＰＡＮＡＳＩＵＫ，Ａ．Ｖ． ｅｔ ａｌ, "［Ｄｉｓｓｅｍｉｎａｔｅｄ ｐｕｌｍｏｎａｒｙ ｔｕｂｅｒｃｕｌｏｓｉｓ， ｄｉａｂｅｔｅｓ ｍｅｌｌｉｔｕｓ ａｎｄ ａｍｙｌｏｉｄｏｓｉｓ ｉｎ ａ ｐａｔｉｅｎｔ ｗｉｔｈ ｈｅｒｅｄｉｔａｒｙ", Ｐｒｏｂｌ Ｔｕｂｅｒｋ, 1988, Ｎｏ．１, ｐ．７２−４ *
JPN7010002274, ＬＩＥＢＥＲＭＡＮ，Ｊ．, "Ａｕｇｍｅｎｔａｔｉｏｎ ｔｈｅｒａｐｙ ｒｅｄｕｃｅｓ ｆｒｅｑｕｅｎｃｙ ｏｆ ｌｕｎｇ ｉｎｆｅｃｔｉｏｎｓ ｉｎ ａｎｔｉｔｒｙｐｓｉｎ ｄｅｆｉｃｉｅｎｃｙ： ａ ｎｅｗ ｈｙｐｏｔｈｅｓｉ", Ｃｈｅｓｔ, 2000, Ｖｏｌ．１１８， Ｎｏ．５, ｐ．１４８０−５ *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5729297B2 (ja) * 2009-07-13 2015-06-03 不二製油株式会社 経口性抗炎症剤及び経口性抗炎症ペプチド
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2020171316A (ja) * 2011-06-24 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2014519852A (ja) * 2011-06-24 2014-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2017079769A (ja) * 2011-06-24 2017-05-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP2019058197A (ja) * 2011-06-24 2019-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
JP2018008956A (ja) * 2011-06-28 2018-01-18 インヒブルクス リミティド パートナーシップ セルピン融合ポリペプチド及びその使用方法
JP2020078325A (ja) * 2011-06-28 2020-05-28 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
US10723785B2 (en) 2011-06-28 2020-07-28 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
US10730929B2 (en) 2011-06-28 2020-08-04 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
JP2014523900A (ja) * 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法
US11046752B2 (en) 2011-06-28 2021-06-29 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
JP2022109968A (ja) * 2011-06-28 2022-07-28 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
US11827691B2 (en) 2011-06-28 2023-11-28 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
US11965017B2 (en) 2011-06-28 2024-04-23 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
JP2024138397A (ja) * 2011-06-28 2024-10-08 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2015519341A (ja) * 2012-05-25 2015-07-09 ウェル リソーシーズ リミテッド ペプチドおよびその使用

Also Published As

Publication number Publication date
US9499606B2 (en) 2016-11-22
EP2520654B1 (en) 2017-02-01
US20050106151A1 (en) 2005-05-19
US20170240615A1 (en) 2017-08-24
EP1660094A4 (en) 2009-09-16
US20140234310A1 (en) 2014-08-21
EP3192872A1 (en) 2017-07-19
US8633305B2 (en) 2014-01-21
WO2005019434A3 (en) 2005-10-06
EP1660094A2 (en) 2006-05-31
US10913790B2 (en) 2021-02-09
CA2536918A1 (en) 2005-03-03
ES2622522T3 (es) 2017-07-06
US20100137192A1 (en) 2010-06-03
PL2520654T3 (pl) 2017-08-31
EP2520654B8 (en) 2017-04-19
US20110021416A1 (en) 2011-01-27
US9695229B2 (en) 2017-07-04
US20120071545A1 (en) 2012-03-22
WO2005019434A2 (en) 2005-03-03
US20200079836A1 (en) 2020-03-12
EP2520654A1 (en) 2012-11-07
US7850970B2 (en) 2010-12-14
US20140370036A1 (en) 2014-12-18
DK2520654T3 (en) 2017-05-01

Similar Documents

Publication Publication Date Title
US10913790B2 (en) Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
JP2010524971A (ja) 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
JPH08508165A (ja) ウシ好中球由来の新規な抗微生物性ペプチド
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
EP1037650B1 (en) Compositions for the treatment of staphylococcus aureus infections
EP2178904B1 (en) Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
US20080095756A1 (en) Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
CN103037887B (zh) 用于治疗呼吸道感染的方法和药物组合物
JP2008524223A (ja) ウイルス感染の治療のための方法および組成物
HK1244500A1 (en) Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
HK1178569A (en) Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
HK1178569B (en) Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2021234527A1 (en) An antibody fragment based antifungal conjugate selectively targeting candida
KR20210141667A (ko) 감염성 심내막염의 치료 방법
KR20190071720A (ko) 주사의 혈관수축성 및 항균성 병용 치료
JP5086633B2 (ja) 細胞内に侵入する能力を有するペプチド及び核酸、物質を細胞内に侵入させるための物質移送用剤及び物質移送方法、並びに、らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬
JP5685562B2 (ja) らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬
CN115209912A (zh) 肽组合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110511